TrialDiabetes2005

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Kevan C Herold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.